Rachel Wade

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

Daniel Catovsky, Estella Matutes, R. F. Bezares et al. · The Lancet · 2007 · 678 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Rachel Wade et al. · The Lancet Oncology · 2013 · 480 citations · Full text

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Chris Mitchell et al. · The Lancet Oncology · 2014 · 301 citations · Full text

Hematological Malignancy, Post-remission Therapy, Young People +13

Mutational Status of the <i>TP53</i> Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

David González, Pilar Martı́nez, Rachel Wade et al. · Journal of Clinical Oncology · 2011 · 263 citations

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003

David O’Connor, Jessica Bate, Rachel Wade et al. · Blood · 2014 · 244 citations